Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olatorepatide in Overweight or Obesity
NCT07685808Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jul 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
A Phase 2 trial of olatorepatide in obesity, sponsored by Regeneron Pharmaceuticals. Started Jul 2026; status: recruiting.
02
Drugs
olatorepatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07685808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07685808.